Patients asked for clearer warnings on antidepressants. The regulator has now agreed
What happened
On 15 October 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) announced changes to the safety information that comes with antidepressant medicines in the UK. The changes follow a major review by the Commission on Human Medicines, the independent expert group that advises UK ministers on medicines. The review began because patients and their families raised concerns about how two particular risks were described in patient information leaflets: suicidal thoughts and behaviours, and sexual problems that carry on after someone stops taking the medicine. Four things will change. First, leaflets will carry a new boxed warning. This is a warning set inside a box so it stands out, pointing readers to the information about suicidal thoughts. Second, a patient card is expected to be included in or on the medicine box. The card repeats the key safety messages and explains where to get help. Third, leaflets for certain antidepressants will start using the term "Post SSRI Sexual Dysfunction", shortened to PSSD. This describes sexual symptoms that may continue after treatment stops. Fourth, the MHRA is working with the wider health system on a supporting safety leaflet. The plan is to give it to people at their first antidepressant appointment, and also to people already taking these medicines. The MHRA expects it to be available in 2027. Dr Alison Cave, the MHRA's Chief Safety Officer, said: "Patients need clear and accessible information about the benefits and risks of medicines so they can make informed decisions."
Why this matters
Antidepressants are among the most widely prescribed medicines in the UK. For a great many people they work, and they make life liveable again. Nothing in this announcement says otherwise. What has changed is how honestly the risks are described on the paper in the box. Take PSSD. For years, some people who stopped taking an SSRI antidepressant reported that sexual side effects did not go away. They often struggled to get this taken seriously, partly because there was no agreed name for it in official leaflets. Putting the term PSSD in writing, in the leaflet, does something quite powerful: it tells a patient that what they are experiencing is a recognised thing, not something they have imagined. The same goes for the boxed warning on suicidal thoughts. That risk was already mentioned in leaflets. The problem was that it could be buried in small print among dozens of other possible effects, at exactly the moment when someone is least able to read carefully. It is also worth noticing how this happened. The review started because patients and families pushed for it, and the MHRA says it worked directly with them, reviewed the latest evidence and took expert clinical advice. NICE joined the expert working group, and will now consider whether its own published guidance needs to change. Chris Bird is NICE's Programme Manager for Patient Safety.
What the evidence actually says
A few things need saying plainly, because this is an area where worry spreads fast. These changes are about information, not about whether the medicines work. The MHRA has not withdrawn any antidepressant, has not restricted who can be prescribed one, and has not said the risks are higher than previously thought. It has said the existing risks should be communicated better. The MHRA's announcement does not include statistics. It gives no numbers on how common suicidal thoughts or PSSD are. So if you see a figure quoted alongside this story, it has come from somewhere else and should be checked. The announcement also does not name which antidepressants will carry the PSSD wording. It says the term applies to "certain antidepressants". PSSD is specifically linked to SSRIs, a common family of antidepressants, but the precise list is not published in this release. The timings differ too. The boxed warning and the patient card are changes to product information that will come through as packs are updated. The separate supporting leaflet is still being developed and is expected in 2027. One point matters above all others. Stopping an antidepressant suddenly can cause withdrawal symptoms and can allow the original illness to return. This announcement is not advice to stop taking anything.
Qurexa perspective
Because we deliver prescription medicines and support people in taking them as prescribed, we see something that does not show up in regulatory documents: the leaflet is often the only part of the health system a person has to hand at 11pm. That is why a boxed warning and a patient card are more than tidying-up. They are designed for a tired, frightened person reading at the kitchen table, not for a clinician with ten minutes to spare. If you take an antidepressant, two practical things follow. When your next pack arrives, read the leaflet again even if you have taken the medicine for years, because the wording may have changed. And if something in it worries you, your community pharmacist can talk it through with you, usually without an appointment and often sooner than a GP can. We would also say this: do not change your dose because of a news story, including this one. Talk to the person who prescribed it.
Practical advice
**Do not stop or change your dose on your own.** Antidepressants usually need to be reduced slowly, with support. Sudden stopping can cause withdrawal effects and can bring the original problem back. **Read the new leaflet when your next pack arrives.** The information is changing, so the leaflet you read two years ago may not match the one in today's box. **Keep the patient card if you get one.** It is meant to live in a wallet or on a noticeboard, not in the recycling. **Tell someone if your mood drops sharply, especially in the first weeks.** The risk of suicidal thoughts is highest early in treatment and after a dose change. This is a reason to stay in contact with your prescriber, not a reason to avoid treatment. **Raise lasting sexual side effects with your prescriber, including after stopping.** There is now an agreed term, PSSD, for symptoms that continue after treatment ends. Having the words makes the conversation easier. **Report side effects through the Yellow Card scheme.** Anyone can do it, patients included, at yellowcard.mhra.gov.uk. Reviews like this one happen because people report things. **If you are in crisis, get help now.** Call 999 or go to A&E if you are in immediate danger. Samaritans is free on 116 123, at any hour.
What to know
The MHRA is strengthening the safety information supplied with antidepressants after a review by the Commission on Human Medicines, prompted by patients and families. Leaflets will gain a boxed warning pointing to the information on suicidal thoughts, a patient card is expected in or on the box, and leaflets for certain antidepressants will use the term PSSD for sexual symptoms that persist after stopping. A separate supporting leaflet, to be handed out at a first antidepressant appointment and to existing patients, is expected in 2027. This is a change in how risks are explained, not a change in the medicines themselves. No antidepressant has been withdrawn or restricted, and the announcement contains no new statistics. The single most important thing to take from it is to read the updated leaflet, raise concerns with your prescriber or pharmacist, and never stop an antidepressant abruptly on your own. Sources: Medicines and Healthcare products Regulatory Agency, "MHRA introduces new safeguards to strengthen antidepressant safety information following major review", 15 October 2026, https://www.gov.uk/government/news/mhra-introduces-new-safeguards-to-strengthen-antidepressant-safety-information-following-major-review; Medicines and Healthcare products Regulatory Agency, Yellow Card scheme for reporting suspected side effects, https://yellowcard.mhra.gov.uk This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. Never start, stop or change a prescribed medicine because of something you have read online. If you are struggling with your mental health, contact your GP, call NHS 111, or call Samaritans free on 116 123.
Related articles
44% of over-75s are active, against 64% of 55 to 74s: the government replies
On 22 October 2026 the government published its formal reply to a report by the House of Commons Health and Social Care Committee. The committee's report is ca…
£9.4 million to move mental health workers into children's social care teams
On 23 October 2026 the government announced a new mental health pilot for children and young people who are supported by children's social care. The pilot is c…
One tablet a day: the UK has licensed a new psoriasis treatment
On 23 October 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) licensed a new medicine for plaque psoriasis. The medicine is called icotroki…